- Home
- GILD vs INTU Comparison
GILD vs INTU Comparison
Compare GILD & INTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | INTU |
|---|---|---|
| Founded | 1987 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 101.4B |
| IPO Year | 2001 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GILD | INTU |
|---|---|---|
| Price | $131.99 | $397.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 20 |
| Target Price | $148.39 | ★ $692.35 |
| AVG Volume (30 Days) | ★ 4.3M | 3.0M |
| Earning Date | 05-07-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.55% | 1.22% |
| EPS Growth | ★ 1684.21 | 31.06 |
| EPS | ★ 6.78 | 4.06 |
| Revenue | ★ $24,689,000,000.00 | $18,831,000,000.00 |
| Revenue This Year | $4.68 | $15.03 |
| Revenue Next Year | $6.04 | $12.41 |
| P/E Ratio | ★ $19.37 | $95.54 |
| Revenue Growth | 9.98 | ★ 15.63 |
| 52 Week Low | $95.30 | $342.11 |
| 52 Week High | $157.29 | $813.48 |
Technical Indicators
Market Signals| Indicator | GILD | INTU |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 48.67 |
| Support Level | $116.55 | $373.96 |
| Resistance Level | $142.33 | $419.00 |
| Average True Range (ATR) | 2.96 | 13.88 |
| MACD | -0.34 | 2.62 |
| Stochastic Oscillator | 33.65 | 63.80 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.